Patents by Inventor Tsuguo Kubota
Tsuguo Kubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406926Abstract: An object of the present invention is to provide a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.Type: ApplicationFiled: February 12, 2021Publication date: December 21, 2023Applicant: Kyowa Kirin Co., Ltd.Inventors: Rinpei NIWA, Shinya OGAWA, Mami WAJIMA, Tsuguo KUBOTA
-
Patent number: 10550181Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: December 9, 2016Date of Patent: February 4, 2020Assignees: KYOWA KIRIN CO., LTD, Kyushu University, National University CorporationInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
-
Patent number: 9695237Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: GrantFiled: September 30, 2015Date of Patent: July 4, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi Ando, Hiroshi Ando, Mariko Nakano, Naoya Kameyama, Tsuguo Kubota
-
Publication number: 20170088616Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: December 9, 2016Publication date: March 30, 2017Applicants: KYOWA HAKKO KIRIN CO., LTD, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Shin-ichiro TAKAYANAGI, Hitomi TOMURA, Tomonori TAWARA, Yoshimasa INAGAKI, Tsuguo KUBOTA, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Patent number: 9556270Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: September 5, 2013Date of Patent: January 31, 2017Assignees: KYOWA HAKKO KIRIN CO., LTD, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
-
Patent number: 9403914Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: December 28, 2010Date of Patent: August 2, 2016Assignee: KYOWA HAKKO KIRIN CO., LTDInventor: Tsuguo Kubota
-
Publication number: 20160060340Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: ApplicationFiled: September 30, 2015Publication date: March 3, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi ANDO, Hiroshi ANDO, Mariko NAKANO, Naoya KAMEYAMA, Tsuguo KUBOTA
-
Patent number: 9207238Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: GrantFiled: November 25, 2013Date of Patent: December 8, 2015Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Munetoshi Ando, Hiroshi Ando, Mariko Nakano, Naoya Kameyama, Tsuguo Kubota
-
Patent number: 9181332Abstract: An anti-A? oligomer humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of A? amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.Type: GrantFiled: November 15, 2012Date of Patent: November 10, 2015Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Tsuguo Kubota, Nobuyuki Suzuki
-
Publication number: 20150158945Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: October 29, 2014Publication date: June 11, 2015Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Norihiko SHIRAISHI, Akiko FURUYA, Hiroe TOKI, Hiroshi ANDO, Masayo SUZUKI, Tsuguo KUBOTA
-
Patent number: 9023999Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: June 30, 2009Date of Patent: May 5, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Katsuhiro Mori, Naoko Hiura, Tsuguo Kubota, Akiko Furuya, Yutaka Kanda, Mitsuo Satoh
-
Patent number: 8969040Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.Type: GrantFiled: July 2, 2013Date of Patent: March 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kiyoshi Shimizu, Yuji Yamazaki, Tsuguo Kubota, Kaname Kimura
-
Patent number: 8945870Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: August 13, 2012Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Patent number: 8877913Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: January 31, 2013Date of Patent: November 4, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomoaki Nakagawa, Sayaka Hori, Rinpei Niwa, Tsuguo Kubota, Kazuhiro Masuda, Kazuyasu Nakamura
-
Publication number: 20140205610Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: ApplicationFiled: November 25, 2013Publication date: July 24, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi ANDO, Hiroshi ANDO, Mariko NAKANO, Naoya KAMEYAMA, Tsuguo KUBOTA
-
Patent number: 8673592Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: July 2, 2013Date of Patent: March 18, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventor: Tsuguo Kubota
-
Publication number: 20140056902Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.Type: ApplicationFiled: July 2, 2013Publication date: February 27, 2014Applicant: Kyowa Hakko Kirin Co., LtdInventors: Kiyoshi SHIMIZU, Yuji YAMAZAKI, Tsuguo KUBOTA, Kaname KIMURA
-
Publication number: 20140044728Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: September 5, 2013Publication date: February 13, 2014Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KYOWA HAKKO KIRIN CO., LTDInventors: Shin-ichiro TAKAYANAGI, Hitomi TOMURA, Tomonori TAWARA, Yoshimasa INAGAKI, Tsuguo KUBOTA, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Publication number: 20130323789Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: July 2, 2013Publication date: December 5, 2013Applicant: KYOWA HAKKO KIRIN CO., LTDInventor: Tsuguo KUBOTA
-
Patent number: 8552156Abstract: The present invention provides an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: June 13, 2011Date of Patent: October 8, 2013Assignees: Kyowa Hakko Kirin Co., Ltd, Kyushu University, National University CorporationInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige